Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition

Biochemistry

Volumn 44, Issue 7, 2005, Pages 2293-2304

  Peng, Sheng Bin ^a   Yan, Lei ^a   Xia, Xiaoling ^a   Watkins, Scott A ^a   Brooks, Harold B ^a   Beight, Douglas ^a   Herron, David K ^a   Jones, Michael L ^a   Lampe, John W ^a   McMillen, William T ^a   Mort, Nicholas ^a   Sawyer, J Scott ^a   Yingling, Jonathan M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINETRIPHOSPHATE; ALCOHOLS; CELL CULTURE; CELLS; GROWTH KINETICS; MORPHOLOGY; NITROGEN COMPOUNDS; SIGNAL PROCESSING;

CELL PROLIFERATION; EXTRACELLULAR MATRIX DEPOSITION; PHOSPHORYLATION; PYRAZOLES;

ENZYME KINETICS;

BONE MORPHOGENETIC PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PYRAZOLE DERIVATIVE; SMAD PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; ENZYME ASSAY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GROWTH INHIBITORS; HELA CELLS; HUMANS; KINETICS; MAP KINASE KINASE KINASES; MASS SPECTROMETRY; MESODERM; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; SERINE; SMAD2 PROTEIN; SMAD3 PROTEIN; SUBSTRATE SPECIFICITY; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 20044375562     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi048851x     Document Type: Article

References (45)

1. Roberts, A. B., and Sporn, M. B. (1990) The transforming growth factor-β in Handbook of Experimental Pharmacology, Peptide, Growth Factors, and Their Receptors (Sporn, M. B., and Roberts, A. B., Eds.) pp 419-472, Springer, Heidelberg, Germany.
2. Derynck, R., and Feng, X. H. (1997) TGF-β receptor signaling, Biochim. Biophys. Acta 133, F105-F150.
3. Yue, J., and Mulder, K. M. (2001) Transforming growth factor-β signal transduction in epithelial cells, Pharmacol. Ther. 91, 1-34.
4. Massagué, J. (1998) TGF-β signal transduction, Annu. Rev. Biochem. 67, 753-791.
5. Wrana, J. L., Attisano, L., Càrcamo, J., Zentella, A., Doodey, J., Laiho, M., Wang, X.-F., and Massagué, J. (1992) TGF β signals through a heteromeric protein kinase receptor complex, Cell 71, 1003-1014.
6. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massagué, J. (1994) Mechanism of activation of the TGF-β receptor, Nature 370, 341-347.
7. ten Dijke, P., Yamashita, H., Ichijo, H., Franzen, P., Laiho, M., Miyazono, K., and Heldin, C. H. (1994) Characterization of type I receptors for transforming growth factor-β and activin, Science 264, 101-104.
8. Wrana, J. L., and Attisano, L. (1996) MAD-related proteins in TGF-β signaling, Trends Genet. 12, 493-496.
9. ten Dijke, P., Miyazono, K., and Heldin, C. H. (2000) Signaling inputs converge on nuclear effectors in TGF-β signaling, Trends Biochem. Sci. 25, 64-70.
10. Massagué, J., and Chen, Y.-G. (2000) Controlling TGF-β signaling, Genes Dev. 14, 627-644.
11. Derynck, R., Akhurst, R. J. and Balmain, A. (2001) TGF-β signaling in tumor suppression and cancer progression, Nat. Genet. 29, 117-129.
12. Siegel, P. M., and Massagué, J. (2003) Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer, Nat. Rev. Cancer 3, 807-820.
13. Hay, E. D. (1995) An overview of epithelio-mesenchymal transformation, Acta Anat. 154, 8-20.
14. Boyer, B., Valles, A. M., and Thiery, J. P. (1996) Model systems of epithelium-mesenchyme transitions, Acta Anat. 156, 227-239.
15. Gilles, C., and Thompson, E. W. (1996) The epithelial to mesenchymal transition and metastatic progression in carcinoma, Breast J. 2, 83-96.
16. Thiery, J. P. (2002) Epithelial-mesenchymal transitions in tumour progression, Nat. Rev. Cancer 2, 442-454.
17. Oft, M., Heider, K. H., and Beug, H. (1998) TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis, Curr. Biol. 8, 1243-1252.
18. Bandyopadhyay, A., Zhu, Y., Cibull, M. L., Bao, L., Chen, C., and Sun, L. (1999) A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res. 59, 5041-5046.
19. Massagué, J., Blain, S. W., and Lo, R. S. (2000) TGFβ signaling in growth control, cancer, and heritable disorders, Cell 103, 295-309.
20. Stahl, P. J., and Felsen, D. (2001) Transforming growth factor-β, basement membrane, and epithelial-mesenchymal transdifferentiation: Implications for fibrosis in kidney disease, Am. J. Pathol. 159, 1187-1192.
21. Yang, J., and Liu, Y. (2001) Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis, Am. J. Pathol. 159, 1465-1475.
22. Chen, R. H., Moses, H. L., Maruoka, E. M., Derynck, R., and Kawabata, M. (1995) Phosphorylation-dependent interaction of the cytoplasmic domains of the type I and type II transforming growth factor-β receptors, J. Biol. Chem. 270, 12235-12241.
23. Franzen, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schulz, P., Heldin, C. H., and Miyazono, K. (1993) Cloning of a TGF β type I receptor that forms a heteromeric complex with the TGF β type II receptor, Cell 75, 681-692.
24. Abdollah, S., Macias-Silva, M., Tsukazaki, T., Hayashi, L. A., and Wrana, J. L. (1997) TβRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling, J. Biol. Chem. 272, 27678-27685.
25. Souchelnytskyi, S., Taraaki, K., Engstrom, U., Wernstedt, C., ten Dijke, P., and Heldin, C. H. (1997) Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling, J. Biol. Chem. 272, 28107-28115.
26. Wieser, R., Wrana, J. L., and Massagué, J. (1995) GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex, EMBO J. 14, 2199-2208.
27. Laping, N. J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., Gaster, L., Callahan, J. F., and Olson, B. A. (2002) Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity. SB-431542, Mol. Pharmacol. 62, 58-64.
28. Inman, G. J., Nicolas, F. J., Lallahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., and Hill, C. S. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7, Mol. Pharmacol. 62, 65-74.
29. DaCosta, B. S., Major, C., Laping, N. J., and Roberts, A. B. (2004) SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7, Mol. Pharmacol. 65, 744-752.
30. Sawyer, J. S., Anderson, B. D., Beigh, D. W., Campbell, R. M., Jones, M. L., Herron, D. K., Lampe, J. W., McCowan, J. R., McMillen, W. T., Mort, N., Parsons, S., Smith, E. C. R., Veith, M., Weir, L. C., Yan, L., and Yingling, J. M. (2003) Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain, J. Med. Chem. 46, 3953-3956.
31. Sawyer, J. S., Anderson, B. D., Beight, D. W., Campbell, R. M., Goodson, T., Jr, Herron, D. K., Li, H. Y., McMillen, W. T., Mort, N., Parsons, S., Smith, E. C., Wagner, J. R., Yan, L., Zhang, F., Yingling, J. M. (2004) Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2- β]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain, Bioorg. Med. Chem. Lett. 14, 3581-3584.
32. Li, H. Y., Wang, Y., Yan, L., Campbell, R. M., Anderson, B. D., Wagner, J. R., and Yingling, J. M. (2004) Novel and potent transforming growth factor β type I receptor kinase domain inhibitor: 7-Amino4-(2-pyridin-2-yl-5,6- dihydro-4H-pyrrolo[1,2-β]pyrazol-3-yl)-quinolines, Bioorg. Med. Chem. Lett. 14, 3585-3588.
33. Singh, J., Ling, L. E., Sawyer, J. S., Lee, W. C., Zhang, F., and Yingling, J. M. (2004) Transforming the TGFβ pathway. Convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5), Curr. Opin. Drug Discovery Dev. 7, 437-445.
34. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L., and Wrana, J. L. (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor, Cell 11, 779-791.
35. Singh, J., Chuaqui, C. E., Boriack-Sjodin, P. A., Lee, W. C., Pontz, T., Corbley, M. J., Cheung, H. K., Arduini, R. M., Mead, J. N., Newman, M. N., Papadatos, J. L., Bowes, S., Josiah, S., and Ling, L. E. (2003) Successful shape-based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI), Bioorg. Med. Chem. Lett. 13, 4355-4359.
36. Lee, J. C., and Adams, J. L. (1995) Inhibitors of serine/threonine kinases, Curr. Opin. Biotechnol. 6, 657-661.
37. Dancey, J., and Sausville, E. A. (2003) Issues and progress with protein kinase inhibitors for cancer treatment, Nat. Rev. Drug Discovery 2, 296-313.
38. Taylor, S., and Radzio-Andzelm, E. (1997) Protein kinase inhibition: Natural and synthetic variations on a theme, Curr. Opin. Chem. Biol. 1, 219-226.
39. Swinney, D. C. (2004) Biochemical mechanisms of drug action: What does it take for success? Nat. Rev. Drug Discovery 3, 801-808.
40. Shingo, M., Hayashi, M., Komiya, S., Imamura, T., and Miyazono, K. (2004) Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells, EMBO J. 23, 552-563.
41. Miettinen, J. P., Ebner, R., Lopez, A. R., and Derynck, R. (1994) TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors, J. Cell. Biol. 127, 2021-2036.
42. Piek, E., Moustakas, A., Kurisaki, A, Heldin, C. H., and ten Dijke, P. (1999) TGF-β type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells, J. Cell Sci. J12, 4557-4568.
43. Ge, R., Rajeev, V., Subramanian, G., Reiss, K. A., Liu, D., Higgins, L., Joly, A., Dugar, S., Chakravarty, J., Henson, M., McEnroe, G., Schreiner, G., and Reiss, M. (2004) Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling, Biochem. Pharmacol. 68, 41-50.
44. Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A. and Arhurst, R. J. (1996) TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice, Cell 86, 531-542.
45. Ottesen, J. J., Huse, M., Sekedat, M. D., and Muir, T. W. (2004) Semisynthesis of phosphovariants of Smad2 reveals a substrate preference of the activated TβRI kinase, Biochemistry 43, 5698-5706.